FENNEC (FENC) CSO Christiana Cioffi Exercises/Converts 155 Shares

What Happened
Christiana Marie Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals (FENC), reported the exercise/conversion of a derivative security resulting in the acquisition of 155 common shares on 2026-04-30. The shares were acquired at an effective price of $0.00 (total cash paid $0), reflecting the release/conversion of previously awarded restricted shares rather than a market purchase or sale.

Key Details

• Transaction date: 2026-04-30; Filing date: 2026-05-01 (timely under Form 4 rules). Accession: 0002043411-26-000006.
• Transaction type/code: M — Exercise or conversion of derivative security. Price per share reported: $0.00; total cash paid: $0.
• Shares involved: 155 shares were acquired/issued.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The filing states these are shares released from restriction from an award dated 2025-03-28.
• No sale reported — shares were converted/released and not immediately sold.

Context
The transaction appears to be the vesting/release or conversion of previously granted restricted shares (per the footnote). Such releases are routine administrative events tied to compensation plans and do not, by themselves, signal a buy or sell opinion by the insider.